Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen

BACKGROUND: In the European Union (EU) and United States (US), specific regulations have been released to provide incentives to develop and sell orphan medicinal products. We analysed the status of orphan drugs designated that not yet received a marketing authorisation or already marketed for patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannuzzi, Viviana, Conte, Rosa, Landi, Annalisa, Ottomano, Serena Antonella, Bonifazi, Donato, Baiardi, Paola, Bonifazi, Fedele, Ceci, Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376695/
https://www.ncbi.nlm.nih.gov/pubmed/28372595
http://dx.doi.org/10.1186/s13023-017-0617-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376695/
https://www.ncbi.nlm.nih.gov/pubmed/28372595
http://dx.doi.org/10.1186/s13023-017-0617-1

Ejemplares similares